BrightGene Bio-Medical Technology Co., Ltd.

Brightgene Bio-medical Technology Co., Ltd. (Stock code: 688166) is a research and development-driven high-tech pharmaceutical company dedicated to the development and production of original new drugs and high-end generic drugs. With professional R&D capabilities and commercialization capabilities, it provides patients with products of excellent value.With the goal of "continuous innovation and health protection", Brightgene seeks solutions for unmet clinical needs. After years of continuous R&D and exploration, Brightgene has made breakthroughs in the field of targeted tumor therapy and immunotherapy, as well as the treatment of fatty liver and diabetes, and many original innovative drugs have entered or are about to enter clinical research. Brightgene has successfully developed high-barrier generic drugs such as Eribulin, Trabectedin, Fondaparinux and other high-end generic drugs, linking up the entire industrial chain from "starting materials → difficult intermediates → specialty APIs → preparations". A number of pharmaceutical intermediates and API products independently developed and produced by the company have been DMF registered in major international regulatory market countries such as the United States, Europe, Japan, Korea and China, and have been cited by customers. They are used in anti-tumor, super antibiotics, intravenous supplements The iron and other fields have established a product line with global competitive advantages. Our main product including Entecavir, Sugammadex Sodium, Eribulin, Trabectedin,Argatroban,Caspofungin,Anidulafungin,Micafungin,Posaconazole,Everolimus,Fondaparinux,Pimecrolimus, Doramectin, Selamectin, AP3, DM1, Ferumoxytol, Ferric CarboxyMaltose, Dalbavancin and so on.